je.st
news
Tag: cell
Ballard Inks Deal to Supply Next-Generation Fuel Cell Power Product for Eight Buses in China
2015-04-21 12:31:13| Industrial Newsroom - All News for Today
VANCOUVER Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) today announced that it has received an order from a Chinese customer to supply its next-generation FCvelocity-HD7 power modules for 8 buses to be deployed in a number of Chinese cities. Ballard expects to ship all of the modules in 2015. Randy MacEwen...
Systematic review of EV battery pack costs suggests economies of scale may push cost toward US$200/kWh without further cell chemistry improvements
2015-04-20 10:55:34| Green Car Congress
Tags: without
review
cost
costs
Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
2015-04-19 14:30:00| Merck.com - Product News
Dateline City: PHILADELPHIA Data Formed the Basis for KEYTRUDA U.S. FDA Submission and Breakthrough Therapy Designation in Advanced NSCLC PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from KEYNOTE-001, a Phase 1b study evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in nave and previously-treated patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
advanced
journal
published
Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
2015-04-19 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of advanced non-small cell lung cancer (NSCLC). Language: English Contact: Media:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
application
license
cell
Assembly Cell handles performance-critical components.
2015-04-17 14:31:07| Industrial Newsroom - All News for Today
Featuring machine vision guided operation, JOT V4 is suited for assembly of small, performance-critical components, including cameras, microphones, speakers, touchscreens, and vibras. Customer can choose modules needed according to requirements, allowing machine functionality to be fine-tuned for future assembly and volume needs. With numerous feeding options and minimal footprint of 0.35 m², desktop solution fits all factory layouts, and comes in both in-line and off-line versions.
Tags: cell
components
assembly
handles
Sites : [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] next »